Compare NRXP & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRXP | VNRX |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 38.2M |
| IPO Year | N/A | N/A |
| Metric | NRXP | VNRX |
|---|---|---|
| Price | $2.36 | $0.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $30.50 | $3.17 |
| AVG Volume (30 Days) | 446.3K | ★ 2.6M |
| Earning Date | 11-17-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $242,000.00 | ★ $1,472,007.00 |
| Revenue This Year | N/A | $55.33 |
| Revenue Next Year | $643.59 | $493.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.48 |
| 52 Week Low | $1.15 | $0.27 |
| 52 Week High | $6.01 | $0.94 |
| Indicator | NRXP | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.23 | 35.58 |
| Support Level | $2.22 | $0.27 |
| Resistance Level | $2.51 | $0.33 |
| Average True Range (ATR) | 0.19 | 0.03 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 68.52 | 31.95 |
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.